Lipocine’s (LPCN) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $8.00 price objective on the specialty pharmaceutical company’s stock. Separately, Wall Street Zen assumed coverage on Lipocine in a report on Saturday, May 17th. They set a […]
HC Wainwright reiterated their buy rating on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $8.00 price objective on the specialty pharmaceutical company’s stock. Separately, Wall Street Zen assumed coverage on Lipocine in a report on Saturday, May 17th. They set a […]
